AbbVie Reports FDA Expanded Label For VENCLEXTA In Combo With Rituximab to Include Info About Patients With Previously-Trated Chronic Lymphocytic Leukemia Who Achieved Minimal Residual Disease Negativity In Phase 3 MURANO Trial